Anzeige
Mehr »
Login
Mittwoch, 02.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Der CEO kauft ein - und das gleich zweimal: Startschuss für die nächste Kursrallye?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 927079 | ISIN: US4523271090 | Ticker-Symbol: ILU
Tradegate
02.04.25
12:03 Uhr
72,87 Euro
+0,24
+0,33 %
1-Jahres-Chart
ILLUMINA INC Chart 1 Jahr
5-Tage-Chart
ILLUMINA INC 5-Tage-Chart
RealtimeGeldBriefZeit
72,2872,6813:29
72,2272,8413:30
PR Newswire
169 Leser
Artikel bewerten:
(0)

Illumina, Inc.: Illumina appoints Everett Cunningham Chief Commercial Officer

Finanznachrichten News

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ:?ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10.

Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. He brings extensive commercial experience across the healthcare tech, life sciences, and pharmaceutical industries. Most recently, Cunningham served as Chief Commercial Officer at Exact Sciences, where he oversaw the company's marketing, sales, and customer service functions. Prior to Exact Sciences, he held various senior leadership roles at Quest Diagnostics, GE Healthcare, and Pfizer, where he spent 21 years as a commercial leader.

Cunningham has a demonstrated track record of success in driving operational excellence, delivering top-line results, and expanding into new markets. He is known as a strong leader who has effectively led teams through transformational change to better serve customers.

"I am thrilled to welcome Everett to the Illumina leadership team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," said Jacob Thaysen, Illumina CEO. "He brings tremendous commercial leadership experience to the role, along with a passion for solving some of the world's most pressing healthcare challenges. I am looking forward to seeing all that he and our global commercial teams can do together, capitalizing on our leadership position in next generation sequencing, and delivering the products, services, and solutions that address customers' most pressing needs."

Cunningham will be relocating to San Diego. He succeeds Bas Verhoef, interim CCO and Head of Region, Europe, since January 2024. Verhoef will continue as Head of Region for Europe beginning June 10.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit?illumina.com?and connect with us on?X (Twitter),?Facebook,?LinkedIn,?Instagram,?TikTok, and?YouTube.

Contacts

Investors:
Salli Schwartz
858-291-6421
[email protected]

Media:
Bonny Fowler
740-641-5579
[email protected]

SOURCE Illumina, Inc.

© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.